
FDA has granted priority review designation for Merck’s request for a supplemental biologics license application for pembrolizumab to treat Merkel cell carcinoma, a rare skin cancer.

FDA has granted priority review designation for Merck’s request for a supplemental biologics license application for pembrolizumab to treat Merkel cell carcinoma, a rare skin cancer.

Patients with multiple sclerosis who smoked cigarettes had higher rates of respiratory complications and increased sedentary lifestyle.

Top news of the day from across the health care landscape.

Some older women undergoing chemotherapy for breast cancer may be more susceptible to declining physical function and inability to recover function.

Combined ipilimumab and nivolumab treatment produced durable responses in patients with melanoma brain metastases.

Supplementing a commonly used treatment approach with an additional inhibitor could help overcome resistance in glioblastoma.

Gordon Vanscoy, PharmD, MBA, explains the challenges patients face when being treated with orphan drugs, and how pharmacists can help overcome these challenges.

Top news of the day from across the health care landscape.

Final approval for Sympazan, the oral soluble film formulation of clobazam, is pending the expiration of the orphan drug exclusivity period for ONFI.

The sugar-removing enzyme may lessen the demand for universal blood donors.

Survivors of breast cancer and their families face long-term cumulative financial implications from treatment and associated costs.

Even as market disruptors such as Amazon raise concerns, pharmacies prove that the services they provide yield valuable patient experiences.

A look at last week's top stories in the world of pharmacy.

Combining pembrolizumab (Keytruda) and an investigational drug could benefit patients with advanced melanoma who have not responded to immunotherapy treatment.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

The approvals of Delstrigo and Pifeltro are based on findings from 2 phase 3 clinical trials.

Medicare Part D plans will be given flexibility to tailor on-formulary drug coverage based on specific indications.

BAY94-9027 (Jivi) is approved for the routine prophylactic treatment of hemophilia A in previously treated adults and adolescents 12 years of age or older.

Cannabidiol treatment increased the production of inflammatory suppressor cells in mice, which reduced the clinical signs of MS.

Study highlights the importance of understanding, addressing, and bridging gaps in achieving viral suppression.

Top news of the day from across the health care landscape.

The FDA has released a warning on cases of rare, serious genital area infections having been reported with sodium-glucose contransporter-2 (SGLT2) inhibitors.

The evolution of specialty pharmacy has raised the stakes for the services that patients expect during treatment.

A synthetic chemical caused the self-destruction of glioblastoma tumor cells transferred from human patients into mice.

Top news of the day from across the health care landscape.

Study shows the safety and efficacy of treatment with sofosbuvir and velpatasvir in adults with recurrent chronic genotypes 1-4 HCV infection after liver transplant.

The study's findings show that patients with HIV will forgo short travel distances and wait times in order to access a health care provider with a positive attitude.

Researchers investigated whether heavy alcohol consumption in early life was associated with high-grade prostate cancer in adulthood.

Eravacycline is a tetracycline-class antibacterial injection that has demonstrated potent activity against multidrug-resistant pathogens.